Suppr超能文献

基于网络药理学分析和实验验证的疏肝益脾颗粒抗非酒精性脂肪性肝病作用机制研究

Mechanism investigation of anti-NAFLD of Shugan Yipi Granule based on network pharmacology analysis and experimental verification.

作者信息

Li Hairong, Niu Lijun, Wang Meiling, Liu Chunmei, Wang Yunlong, Su Yu, Yang Yubin

机构信息

West China Second University Hospital, Sichuan University, Chengdu, 610000, China.

Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China.

出版信息

Heliyon. 2024 Aug 5;10(15):e35491. doi: 10.1016/j.heliyon.2024.e35491. eCollection 2024 Aug 15.

Abstract

As a classical traditional Chinese patent medicine, Shugan Yipi Granule is widely used in China to treat non-alcoholic fatty liver disease (NAFLD) recently. Our previous study confirmed that Shugan Yipi Granule are effective in NAFLD. However, its underlying mechanism is still unknown. This study aims to investigate the mechanism of Shugan Yipi Granule on NAFLD based on network pharmacology prediction, liquid chromatography-mass spectrometry (LC-MS) analysis and in vitro verification. We obtained the active ingredients and targets of Shugan Yipi Granule and NAFLD from 6 traditional Chinese medicine databases, and the crucial components and targets screened by protein-protein interaction (PPI) network were used for molecular docking. Plasma metabolomics of NAFLD patients treated with Shugan Yipi Granule for one month was analyzed using LC-MS methods and MetaboAnalyst 4.0 to obtain significant differential metabolites and pathways. Finally, free fatty acid (FFA) induced HepG2 cells were treated with different concentrations of quercetin and kaempferol, then oil red o (ORO) and triglyceride (TG) level were tested to verify the lipid deposition of the cell. Network pharmacology analysis showed that the main active ingredients of Shugan Yipi Granule include quercetin, kaempferol and other 58 ones, as well as 188 potential targets. PI3K/Akt signaling pathway was found to be the most relevant pathway for the treatment of NAFLD. Non-targeted metabolomics showed that quercetin and kaempferol were significantly up-regulated differential metabolites and were involved in metabolic pathways such as thyroid hormone signaling. In vitro results showed that quercetin, kaempferol were effective in reducing lipid deposition and TG content by inhibiting cellular fatty acid uptake. Ultimately, with the network pharmacology and serum metabolomics analysis, quercetin and kaempferol were found to be the important active ingredients and significantly up-regulated differential metabolites of Shugan Yipi Granule against NAFLD, which we inferred that they may regulate NAFLD through PI3K/Akt signaling pathway and thyroid hormone metabolism pathway. The in vitro experiment verification results showed that quercetin and kaempferol attenuated the lipid accumulation and TG content by inhibiting the fatty acid uptake in the FFA-induced HepG2 cell. Current study provides the necessary experimental basis for subsequent in-depth mechanism research.

摘要

作为一种经典的中成药,疏肝益脾颗粒最近在中国被广泛用于治疗非酒精性脂肪性肝病(NAFLD)。我们之前的研究证实疏肝益脾颗粒对NAFLD有效。然而,其潜在机制仍不清楚。本研究旨在基于网络药理学预测、液相色谱-质谱联用(LC-MS)分析和体外验证,探讨疏肝益脾颗粒治疗NAFLD的机制。我们从6个中药数据库中获取了疏肝益脾颗粒和NAFLD的活性成分及靶点,并将通过蛋白质-蛋白质相互作用(PPI)网络筛选出的关键成分和靶点用于分子对接。采用LC-MS方法和MetaboAnalyst 4.0分析疏肝益脾颗粒治疗1个月的NAFLD患者的血浆代谢组学,以获得显著差异代谢物和代谢途径。最后,用不同浓度的槲皮素和山柰酚处理游离脂肪酸(FFA)诱导的HepG2细胞,然后检测油红O(ORO)和甘油三酯(TG)水平,以验证细胞的脂质沉积情况。网络药理学分析表明,疏肝益脾颗粒的主要活性成分包括槲皮素、山柰酚等58种成分,以及188个潜在靶点。发现PI3K/Akt信号通路是治疗NAFLD最相关的通路。非靶向代谢组学表明,槲皮素和山柰酚是显著上调的差异代谢物,参与甲状腺激素信号等代谢途径。体外实验结果表明,槲皮素、山柰酚通过抑制细胞脂肪酸摄取,有效减少脂质沉积和TG含量。最终,通过网络药理学和血清代谢组学分析,发现槲皮素和山柰酚是疏肝益脾颗粒抗NAFLD的重要活性成分和显著上调的差异代谢物,我们推断它们可能通过PI3K/Akt信号通路和甲状腺激素代谢途径调节NAFLD。体外实验验证结果表明,槲皮素和山柰酚通过抑制FFA诱导的HepG2细胞中的脂肪酸摄取,减轻脂质积累和TG含量。本研究为后续深入的机制研究提供了必要的实验依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee61/11336705/fc85f9777d85/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验